Aripiprazole in the Treatment of Delirium

Alao, Adekola O.; Soderberg, Maureen; Pohl, Elyssa L.; Koss, Marvin

doi:10.2190/33jh-ktv4-be2w-aw05

Cited by 20 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar responses to quetiapine and amisulpiride were reported in an open randomized prospective study [30]. Aripiprazole has also been reported in case reports [56,57] and a case series [58] to be of benefit in treating delirium.…”

Section: Atypical Antipsychoticssupporting

confidence: 71%

Drug treatment of delirium: Past, present and future

Bourne

Tahir

Borthwick

et al. 2008

Journal of Psychosomatic Research

View full text Add to dashboard Cite

Section: Atypical Antipsychoticssupporting

confidence: 71%

Drug treatment of delirium: Past, present and future

Bourne

Tahir

Borthwick

et al. 2008

Journal of Psychosomatic Research

View full text Add to dashboard Cite

“…Perospirone has been reported to be the fourth AP (after risperidone, quetiapine, haloperidol, and followed by olanzapine and aripiprazole) in a large study of 2453 patients treated for delirium [44]. Aripiprazole, which has D2 and 5-HT1A partial agonist properties, has been successfully used in delirium [66,67], particularly in the hypoactive subtype [68], with a low rate of adverse side effect [69,70]. Amisulpride, also an antipsychotic with atypical properties, showed a comparable efficacy and tolerability with quetiapine in one study [71] and a significant improvement of delirium symptoms in another study of medically ill patients with delirium [72].…”

Section: Antipsychotics (Aps)mentioning

confidence: 99%

Management of Delirium in Palliative Care: a Review

Grassi

Caraceni

Mitchell

et al. 2015

Curr Psychiatry Rep

View full text Add to dashboard Cite

Delirium is a complex but common disorder in palliative care with a prevalence between 13 and 88 % but a particular frequency at the end of life (terminal delirium). By reviewing the most relevant studies (MEDLINE, EMBASE, PsycLit, PsycInfo, Cochrane Library), a correct assessment to make the diagnosis (e.g., DSM-5, delirium assessment tools), the identification of the possible etiological factors, and the application of multicomponent and integrated interventions were reported as the correct steps to effectively manage delirium in palliative care. In terms of medications, both conventional (e.g., haloperidol) and atypical antipsychotics (e.g., olanzapine, risperidone, quetiapine, aripiprazole) were shown to be equally effective in the treatment of delirium. No recommendation was possible in palliative care regarding the use of other drugs (e.g., α-2 receptors agonists, psychostimulants, cholinesterase inhibitors, melatonergic drugs). Non-pharmacological interventions (e.g., behavioral and educational) were also shown to be important in the management of delirium. More research is necessary to clarify how to more thoroughly manage delirium in palliative care.

show abstract

“…The authors also reported the case of a 37‐year‐old woman with alcohol‐withdrawal delirium who was treated with 15‐mg aripiprazole. The patients' Mini‐Mental State Examination scores improved (from 5 to 28 and from 7 to 27, respectively) while their Delirium Rating Scale scores decreased (from 28 to 6 and from 18 to 6, respectively) …”

Section: Literature Review Of the Efficacy And Safety Of Aripiprazolementioning

confidence: 97%

“…The patients' Mini-Mental State Examination scores improved (from 5 to 28 and from 7 to 27, respectively) while their Delirium Rating Scale scores decreased (from 28 to 6 and from 18 to 6, respectively). 87,88 Straker et al evaluated the effect of aripiprazole at 5-15 mg/day (average: 8.9 mg/day) for delirium in 14 patients aged 18 to 85 years. A Delirium Rating Scale-Revised-98 improvement of 50% or more was seen in half of the patients by day 5 and in 12 patients by the end of treatment.…”

Section: Literature Review Of the Efficacy And Safety Of Aripiprazolementioning

confidence: 99%

Use of aripiprazole for delirium in the elderly: a short review

Kirino

2014

Psychogeriatrics

View full text Add to dashboard Cite

The effects and tolerability of antipsychotics in delirium treatment remain controversial. Compared to other antipsychotics, aripiprazole differs in pharmacological activity because it exerts its effect as a dopamine D2 partial agonist. The guidelines of the American Psychiatric Association rank aripiprazole highly among antipsychotics with regard to safety, and this drug is likely to be useful for delirium treatment. Here, we reviewed the efficacy and safety of aripiprazole for delirium. The results of our literature review on the efficacy and safety of delirium treatments suggest that aripiprazole is an effective treatment option for delirium in the elderly. Aripiprazole is as effective as other antipsychotics in improving delirium symptoms, and it is safer because it is less likely to cause extrapyramidal symptoms, excessive sedation, and weight gain. However, these findings are based on only a few clinical studies of elderly patients with delirium. Therefore, further investigations are necessary.

show abstract

Aripiprazole in the Treatment of Delirium

Abstract: Aripiprazole appears to be effective in reducing the symptoms of delirium.

Cited by 20 publications

References 7 publications

Drug treatment of delirium: Past, present and future

Drug treatment of delirium: Past, present and future

Management of Delirium in Palliative Care: a Review

Use of aripiprazole for delirium in the elderly: a short review

Contact Info

Product

Resources

About